The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...

Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit in patients with inflammatory bowel disease (IBD). Evidence Rating Level: ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

Janssen’s Stelara has gained FDA approval for use in patients with Crohn’s disease who have failed treatment or were intolerant to a TNF blocker drug. The monoclonal antibody drug targets ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active Crohn's disease, drugmaker Eli Lilly announced; the first-in-class interleukin-23 ...

In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the ... alongside the IL-12/23 blockbuster Stelara (ustekinumab, Janssen) and a logjam ...

In Crohn's disease patients, adherence to a Mediterranean ... (Gastroenterology) Combing 5-aminosalicylic acid with ustekinumab (Stelara) did not appear to provide a clinical benefit in IBD ...

The US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz), from US pharma major Eli Lilly (NYSE: LLY), for the treatment of moderately to severely active Crohn's disease in ...